Skip to main content
SpringerLink
Log in

Epilepsy and Diffuse Low-Grade Gliomas

  • Chapter
  • First Online:
Book cover Diffuse Low-Grade Gliomas in Adults

  • 1072 Accesses

Abstract

World Health Organization diffuse low-grade gliomas (DLGGs) are highly epileptogenic primary brain tumors. Here, we will discuss the incidence and predictors of epileptic seizures and of seizure control, the pathophysiological epileptogenic mechanisms, the impact of oncological treatments on epileptic seizures, and their prognostic significance. Epileptic seizures occur in more than 90% of cases at diagnosis and their predictors are male gender, age, eloquent tumor locations and the presence of competitive other symptoms. Epileptic seizures progress together with drug resistance during the course of DLGG despite treatments and predictors of uncontrolled seizures are simple partial seizures, motor seizures, long duration from seizure onset to oncological treatment, temporal lobe, insular lobe and central area involvement. Epileptogenic foci are nested within the peritumoral neocortex infiltrated by sparse glioma cells and glioma-related epileptogenic mechanisms are multifactorial and intermixed. An excessive glutamatergic excitatory neurotransmission is induced by a high extracellular glutamate concentration resulting from a decrease in glutamate uptake and from an increase in glutamate release by glioma cells and by neighbouring non-tumor cells. An impaired GABAergic signaling is induced by reduced GABAergic inhibitory pathways and functioning and by pathological changes in neuronal chloride homeostasis that switch GABAergic signaling from hyperpolarizing to depolarizing. The short seizure duration before surgery and the extent of resection are main predictors of postoperative seizure control in DLGG and a supratotal resection encompassing the epileptogenic foci in the peripheral neocortex surrounding the DLGG can improve seizure control. Last, epileptic seizure independently impacts DLGG prognosis, as both malignant progression-free survival and overall survival are longer in patients with a history of epileptic seizures.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pallud J, Audureau E, Blonski M, Sanai N, Bauchet L, Fontaine D, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain. 2014;137(Pt 2):449–62.

    Article  PubMed  Google Scholar 

  2. Pallud J, Capelle L, Huberfeld G. Tumoral epileptogenicity: how does it happen? Epilepsia. 2013;54(Suppl. 9):29–33.

    Google Scholar 

  3. van Breemen MSM, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6(5):421–30.

    Article  PubMed  Google Scholar 

  4. Klein M, Engelberts NHJ, van der Ploeg HM, Kasteleijn-Nolst Trenité DGA, Aaronson NK, Taphoorn MJB, et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol. 2003;54(4):514–20.

    Article  PubMed  Google Scholar 

  5. Ruda R, Bello L, Duffau H, Soffietti R. Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro-Oncology. 2012;14(Suppl 4):iv55–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Soffietti R, Baumert BG, Bello L, Deimling Von A, Duffau H, Frénay M, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO* task force. Eur J Neurol. 2010;17(9):1124–33.

    Article  CAS  PubMed  Google Scholar 

  7. Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg. 2008;108(2):227–35.

    Article  PubMed  Google Scholar 

  8. You G, Sha Z-Y, Yan W, Zhang W, Wang Y-Z, Li S-W, et al. Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. Neuro-Oncology. 2012;14(2):230–41.

    Article  PubMed  Google Scholar 

  9. Englot DJ, Berger MS, Barbaro NM, Chang EF. Predictors of seizure freedom after resection of supratentorial low-grade gliomas: a review. J Neurosurg. 2011;115(2):240–4.

    Article  PubMed  Google Scholar 

  10. Fisher RS, van Emde BW, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46(4):470–2.

    Article  PubMed  Google Scholar 

  11. Vercueil L. Brain tumor epilepsy: a reappraisal and six remaining issues to be debated. Rev Neurol (Paris). 2011;167(10):751–61.

    Article  CAS  Google Scholar 

  12. Smits A, Duffau H. Seizures and the natural history of WHO grade II gliomas: a review. Neurosurgery. 2011;68(5):1326–33.

    Article  PubMed  Google Scholar 

  13. Pallud J, Fontaine D, Duffau H, Mandonnet E, Sanai N, Taillandier L, et al. Natural history of incidental World Health Organization grade II gliomas. Ann Neurol. 2010;68(5):727–33.

    Article  PubMed  Google Scholar 

  14. Brogna C, Gil Robles S, Duffau H. Brain tumors and epilepsy. Expert Rev Neurother. 2008;8(6):941–55.

    Article  PubMed  Google Scholar 

  15. Duffau H, Capelle L. Preferential brain locations of low-grade gliomas. Cancer. 2004;100(12):2622–6.

    Article  PubMed  Google Scholar 

  16. Duffau H. A personal consecutive series of surgically treated 51 cases of insular WHO grade II glioma: advances and limitations. J Neurosurg. 2009;110(4):696–708.

    Article  PubMed  Google Scholar 

  17. Ghareeb F, Duffau H. Intractable epilepsy in paralimbic Word Health Organization grade II gliomas: should the hippocampus be resected when not invaded by the tumor? J Neurosurg. 2012;116(6):1226–34.

    Article  PubMed  Google Scholar 

  18. Lee JW, Wen PY, Hurwitz S, Black P, Kesari S, Drappatz J, et al. Morphological characteristics of brain tumors causing seizures. Arch Neurol. 2010;67(3):336–42.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Taillandier L, Duffau H. Epilepsy and insular grade II gliomas: an interdisciplinary point of view from a retrospective monocentric series of 46 cases. Neurosurg Focus. 2009;27(2):E8.

    Article  PubMed  Google Scholar 

  20. Yuan Y, Xiang W, Yanhui L, Ruofei L, Shuang L, Yingjun F, et al. Ki-67 overexpression in WHO grade II gliomas is associated with poor postoperative seizure control. Seizure. European Journal of Epilepsy. BEA Trading Ltd2013;22(10):877–81.

    Article  PubMed  Google Scholar 

  21. Liubinas SV, D'Abaco GM, Moffat BM, Gonzales M, Feleppa F, Nowell CJ, et al. IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas. Epilepsia. 2014;55(9):1438–43.

    Article  CAS  PubMed  Google Scholar 

  22. Stockhammer F, Misch M, Helms H-J, Lengler U, Prall F, Deimling Von A, et al. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure. European Journal of Epilepsy. BEA Trading Ltd2012;21(3):194–7.

    Article  PubMed  Google Scholar 

  23. Zhong Z, Wang Z, Wang Y, You G, Jiang T. IDH1/2 mutation is associated with seizure as an initial symptom in low-grade glioma: a report of 311 Chinese adult glioma patients. Epilepsy Res. 2015;109:100–5.

    Article  CAS  PubMed  Google Scholar 

  24. Mulligan L, Ryan E, O'Brien M, Looby S, Heffernan J, O'Sullivan J, et al. Genetic features of oligodendrogliomas and presence of seizures. The relationship of seizures and genetics in LGOs. Clin Neuropathol. 2014;33(4):292–8.

    Article  PubMed  Google Scholar 

  25. Huang L, You G, Jiang T, Li G, Li S, Wang Z. Correlation between tumor-related seizures and molecular genetic profile in 103 Chinese patients with low-grade gliomas: a preliminary study. J Neurol Sci. 2011;302(1–2):63–7.

    Article  CAS  PubMed  Google Scholar 

  26. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2009;51(6):1069–77.

    Article  PubMed  Google Scholar 

  27. Schucht P, Ghareeb F, Duffau H. Surgery for low-grade glioma infiltrating the central cerebral region: location as a predictive factor for neurological deficit, epileptological outcome, and quality of life. J Neurosurg. 2013;119(2):318–23.

    Article  PubMed  Google Scholar 

  28. Huberfeld G, Vecht CJ. Seizures and gliomas—towards a single therapeutic approach. Nat Rev Neurol. 2016;12(4):204–16.

    Article  PubMed  Google Scholar 

  29. Hirsch JF, Buisson-Ferey J, Sachs M, Hirsch JC, Scherrer J. Electrocorticogram and unitary activites with expanding lesions in man. Electroencephalogr Clin Neurophysiol. 1966;21(5):417–28.

    Article  CAS  PubMed  Google Scholar 

  30. Köhling R, Senner V, Paulus W, Speckmann E-J. Epileptiform activity preferentially arises outside tumor invasion zone in glioma xenotransplants. Neurobiol Dis. 2006;22(1):64–75.

    Article  PubMed  Google Scholar 

  31. Buckingham SC, Campbell SL, Haas BR, Montana V, Robel S, Ogunrinu T, et al. Glutamate release by primary brain tumors induces epileptic activity. Nat Med. 2011;17(10):1269–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Haglund MM, Berger MS, Kunkel DD, Franck JE, Ghatan S, Ojemann GA. Changes in gamma-aminobutyric acid and somatostatin in epileptic cortex associated with low-grade gliomas. J Neurosurg. 1992;77(2):209–16.

    Article  CAS  PubMed  Google Scholar 

  33. de Groot M, Reijneveld JC, Aronica E, Heimans JJ. Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment. Brain. 2012;135(Pt 4):1002–16.

    Article  PubMed  Google Scholar 

  34. Pallud J, Le Van Quyen M, Bielle F, Pellegrino C, Varlet P, Labussiere M, et al. Cortical GABAergic excitation contributes to epileptic activities around human glioma. Sci Transl Med 2014;6(244):244ra89–9.

    Google Scholar 

  35. Beaumont A, Whittle IR. The pathogenesis of tumour associated epilepsy. Acta Neurochir (Wien). 2000;142(1):1–15.

    Article  CAS  Google Scholar 

  36. Shamji MF, Fric-Shamji EC, Benoit BG. Brain tumors and epilepsy: pathophysiology of peritumoral changes. Neurosurg Rev. 2009;32(3):275–84. discussion 284–6

    Article  PubMed  Google Scholar 

  37. Buckingham SC, Robel S. Glutamate and tumor-associated epilepsy: glial cell dysfunction in the peritumoral environment. Neurochem Int. 2013;63(7):696–701.

    Article  CAS  PubMed  Google Scholar 

  38. Savaskan NE, Heckel A, Hahnen E, Engelhorn T, Doerfler A, Ganslandt O, et al. Small interfering RNA–mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat Med. 2008;14(6):629–32.

    Article  CAS  PubMed  Google Scholar 

  39. De Groot J, Sontheimer H. Glutamate and the biology of gliomas. Glia. 2011;59(8):1181–9.

    Article  PubMed  Google Scholar 

  40. Yuen TI, Morokoff AP, Bjorksten A, D'Abaco G, Paradiso L, Finch S, et al. Glutamate is associated with a higher risk of seizures in patients with gliomas. Neurology. 2012;79(9):883–9.

    Article  CAS  PubMed  Google Scholar 

  41. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nat Med. 2001;7(9):1010–5.

    Article  CAS  PubMed  Google Scholar 

  42. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27(25):4150–4.

    Article  CAS  PubMed  Google Scholar 

  43. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 2012;4(116):116ra4.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res. 2007;67(19):9463–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Bianchi L, De Micheli E, Bricolo A, Ballini C, Fattori M, Venturi C, et al. Extracellular levels of amino acids and choline in human high grade gliomas: an intraoperative microdialysis study. Neurochem Res. 2004;29(1):325–34.

    Article  CAS  PubMed  Google Scholar 

  46. Habela CW, Ernest NJ, Swindall AF, Sontheimer H. Chloride accumulation drives volume dynamics underlying cell proliferation and migration. J Neurophysiol. 2009;101(2):750–7.

    Article  CAS  PubMed  Google Scholar 

  47. Marco P, Sola RG, Ramón Y, Cajal S, De Felipe J. Loss of inhibitory synapses on the soma and axon initial segment of pyramidal cells in human epileptic peritumoural neocortex: implications for epilepsy. Brain Res Bull. 1997;44(1):47–66.

    Article  CAS  PubMed  Google Scholar 

  48. Huberfeld G, Wittner L, Clemenceau S, Baulac M, Kaila K, Miles R, et al. Perturbed chloride homeostasis and GABAergic signaling in human temporal lobe epilepsy. J Neurosci. 2007;27(37):9866–73.

    Article  CAS  PubMed  Google Scholar 

  49. Haas BR, Sontheimer H. Inhibition of the sodium-potassium-chloride cotransporter isoform-1 reduces glioma invasion. Cancer Res. 2010;70(13):5597–606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Conti L, Palma E, Roseti C, Lauro C, Cipriani R, de Groot M, et al. Anomalous levels of Cl- transporters cause a decrease of GABAergic inhibition in human peritumoral epileptic cortex. Epilepsia. 2011;52(9):1635–44.

    Article  CAS  PubMed  Google Scholar 

  51. Garzon-Muvdi T, Schiapparelli P, Ap Rhys C, Guerrero-Cazares H, Smith C, Kim D-H, et al. Regulation of brain tumor dispersal by NKCC1 through a novel role in focal adhesion regulation. PLoS Biol. 2012;10(5):e1001320.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Ernest NJ, Weaver AK, Van Duyn LB, Sontheimer HW. Relative contribution of chloride channels and transporters to regulatory volume decrease in human glioma cells. Am J Physiol Cell Physiol. 2005;288(6):C1451–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Campbell SL, Robel S, Cuddapah VA, Robert S, Buckingham SC, Kahle KT, et al. GABAergic disinhibition and impaired KCC2 cotransporter activity underlie tumor-associated epilepsy. Glia. 2014;63(1):23–36.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Aronica E, Boer K, Redeker S, Spliet WGM, van Rijen PC, Troost D, et al. Differential expression patterns of chloride transporters, Na+-K+-2Cl–cotransporter and K+-Cl−-cotransporter, in epilepsy-associated malformations of cortical development. Neuroscience. 2007;145(1):185–96.

    Article  CAS  PubMed  Google Scholar 

  55. Coull JAM, Beggs S, Boudreau D, Boivin D, Tsuda M, Inoue K, et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature. 2005;438(7070):1017–21.

    Article  CAS  PubMed  Google Scholar 

  56. Olsen ML, Sontheimer H. Functional implications for Kir4.1 channels in glial biology: from K+ buffering to cell differentiation. J Neurochem. 2008;107(3):589–601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Hwang S-L, Lin C-L, Lee K-S, Lieu A-S, Kuo T-H, Chang C-Z, et al. Factors influencing seizures in adult patients with supratentorial astrocytic tumors. Acta Neurochir (Wien). 2004;146(6):589–94.

    Article  Google Scholar 

  58. Deras P, Moulinié G, Maldonado IL, Moritz-Gasser S, Duffau H, Bertram L. Intermittent general anesthesia with controlled ventilation for asleep-awake-asleep brain surgery: a prospective series of 140 gliomas in eloquent areas. Neurosurgery. 2012;71(4):764–71.

    Article  PubMed  Google Scholar 

  59. Boetto J, Bertram L, Moulinié G, Herbet G, Moritz-Gasser S, Duffau H. Low rate of intraoperative seizures during awake craniotomy in a prospective cohort with 374 supratentorial brain lesions: electrocorticography is not mandatory. World Neurosurg. 2015;84(6):1838–44.

    Article  PubMed  Google Scholar 

  60. Pallud J, Varlet P, Devaux B, Geha S, Badoual M, Deroulers C, et al. Diffuse low-grade oligodendrogliomas extend beyond MRI-defined abnormalities. Neurology. 2010;74(21):1724–31.

    Article  CAS  PubMed  Google Scholar 

  61. Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO grade II gliomas within “noneloquent” areas in the left dominant hemisphere: toward a “supratotal” resection: clinical article. J Neurosurg. 2011;115(2):232–9.

    Article  PubMed  Google Scholar 

  62. Duffau H. Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up. Acta Neurochir (Wien). 2016;158(1):51–8.

    Article  Google Scholar 

  63. Afra D, Osztie E, Sipos L, Vitanovics D. Preoperative history and postoperative survival of supratentorial low-grade astrocytomas. Br J Neurosurg. 1999;13(3):299–305.

    Article  CAS  PubMed  Google Scholar 

  64. Martino J, Taillandier L, Moritz-Gasser S, Gatignol P, Duffau H. Re-operation is a safe and effective therapeutic strategy in recurrent WHO grade II gliomas within eloquent areas. Acta Neurochir (Wien). 2009;151(5):427–36. discussion 436

    Article  Google Scholar 

  65. Blonski M, Taillandier L, Herbet G, Maldonado IL, Beauchesne P, Fabbro M, et al. Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. J Neuro-Oncol. 2011;106(2):353–66.

    Article  Google Scholar 

  66. Blonski M, Pallud J, Gozé C, Mandonnet E, Rigau V, Bauchet L, et al. Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients. J Neuro-Oncol. 2013;113(2):267–75.

    Article  CAS  Google Scholar 

  67. Berger MS, Ghatan S, Haglund MM, Dobbins J, Ojemann GA. Low-grade gliomas associated with intractable epilepsy: seizure outcome utilizing electrocorticography during tumor resection. J Neurosurg. 1993;79(1):62–9.

    Article  CAS  PubMed  Google Scholar 

  68. Ruda R, Magliola U, Bertero L, Trevisan E, Bosa C, Mantovani C, et al. Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. Neuro-Oncology. 2013;15(12):1739–49.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Rossi GF, Scerrati M, Roselli R. Epileptogenic cerebral low-grade tumors: effect of interstitial stereotactic irradiation on seizures. Appl Neurophysiol. 1985;48(1–6):127–32.

    CAS  PubMed  Google Scholar 

  70. Warnke PC, Berlis A, Weyerbrock A, Ostertag CB. Significant reduction of seizure incidence and increase of benzodiazepine receptor density after interstitial radiosurgery in low-grade gliomas. Acta Neurochir Suppl. 1997;68:90–2.

    CAS  PubMed  Google Scholar 

  71. Pallud J, Llitjos J-F, Dhermain F, Varlet P, Dezamis E, Devaux B, et al. Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas. Neuro-Oncology. 2012;14(4):496–505.

    Article  PubMed  PubMed Central  Google Scholar 

  72. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366(9490):985–90.

    Article  PubMed  Google Scholar 

  73. Kiebert GM, Curran D, Aaronson NK, Bolla M, Menten J, Rutten EH, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer. 1998;34(12):1902–9.

    Article  CAS  PubMed  Google Scholar 

  74. Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003;14(12):1715–21.

    Article  CAS  PubMed  Google Scholar 

  75. Ngo L, Nei M, Glass J. Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma. Epilepsia. 2006;47(7):1237–8.

    Article  PubMed  Google Scholar 

  76. Pace A, Vidiri A, Galiè E, Carosi M, Telera S, Cianciulli AM, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003;14(12):1722–6.

    Article  CAS  PubMed  Google Scholar 

  77. Sherman JH, Moldovan K, Yeoh HK, Starke RM, Pouratian N, Shaffrey ME, et al. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg. 2011;114(6):1617–21.

    Article  PubMed  Google Scholar 

  78. Frenay MP, Fontaine D, Vandenbos F, Lebrun C. First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas. Eur J Neurol. 2005;12(9):685–90.

    Article  CAS  PubMed  Google Scholar 

  79. Lebrun C, Fontaine D, Bourg V, Ramaioli A, Chanalet S, Vandenbos F, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol. Wiley Online Library2007;14(4):391–8.

    Article  CAS  PubMed  Google Scholar 

  80. Pallud J, Mandonnet E, Deroulers C, Fontaine D, Badoual M, Capelle L, et al. Pregnancy increases the growth rates of World Health Organization grade II gliomas. Ann Neurol. 2010;67(3):398–404.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Sainte-Anne Hospital, 1, rue Cabanis, 75674, Paris Cedex 14, France

    Johan Pallud MD, PhD

  2. Paris Descartes University, Sorbonne Paris Cité, Paris, France

    Johan Pallud MD, PhD

  3. Réseau d’Etude des Gliomes, REG, Groland, France

    Johan Pallud MD, PhD

Authors
  1. Johan Pallud MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johan Pallud MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Neurosurgery, Montpellier University Medical Center, INSERM U1051, Institute for Neurosciences of Montpellier, Montpellier, France

    Hugues Duffau

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag London Ltd.

About this chapter

Cite this chapter

Pallud, J. (2017). Epilepsy and Diffuse Low-Grade Gliomas. In: Duffau, H. (eds) Diffuse Low-Grade Gliomas in Adults. Springer, Cham. https://doi.org/10.1007/978-3-319-55466-2_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-55466-2_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-55464-8

  • Online ISBN: 978-3-319-55466-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation